Document is current
Any future updates will be listed below
-
Authors
Wang, Naitao
Pachai, Mohini R.
Li, Dan https://orcid.org/0000-0002-8777-4580
Lee, Cindy J.
Warda, Sarah https://orcid.org/0000-0001-8067-8804
Khudoynazarova, Makhzuna N.
Cho, Woo Hyun https://orcid.org/0009-0009-6451-8996
Xie, Guojia
Shah, Sagar R.
Yao, Li https://orcid.org/0000-0003-2827-8824
Qian, Cheng
Wong, Elissa W. P.
Yan, Juan
Tomas, Fanny V.
Hu, Wenhuo
Kuo, Fengshen https://orcid.org/0000-0003-1797-2896
Gao, Sizhi P.
Luo, Jiaqian https://orcid.org/0000-0002-0062-4716
Smith, Alison E. https://orcid.org/0000-0003-2385-1011
Han, Ming
Gao, Dong https://orcid.org/0000-0003-1821-2741
Ge, Kai
Yu, Haiyuan https://orcid.org/0000-0001-7597-6049
Chandarlapaty, Sarat https://orcid.org/0000-0003-4532-8053
Iyer, Gopakumar V. https://orcid.org/0000-0002-5093-6099
Rosenberg, Jonathan E.
Solit, David B. https://orcid.org/0000-0002-6614-802X
Al-Ahmadie, Hikmat A. https://orcid.org/0000-0002-2938-6627
Chi, Ping https://orcid.org/0000-0002-0159-5531
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA092629, R01CA193837, U01CA224044, R01CA208100, P50CA221745, P50CA221745, P50CA221745, P50CA221745, P01CA221757, R01CA233899, P50CA221745, R01CA228216, DP2CA174499, P50CA217694)
Samuel Waxman Cancer Research Foundation
U.S. Department of Defense (W81XWH-15-1-0124)
- License Information
-
More Information
Article History
Received: 20 June 2023
Accepted: 23 October 2024
First Online: 13 January 2025
Competing interests
: P.C. has received personal honoraria/advisory boards/consulting fees from Deciphera, Exelixis, Zai Lab, Novartis and Ningbo NewBay Medical Technology. P.C. has received institutional research funding from Pfizer/Array, Novartis, Deciphera and Ningbo NewBay Medical Technology. Y.C. has stock ownership and received royalties from Oric Pharmaceuticals. S.C. has received institutional research support from Daiichi-Sankyo, Paige.ai and AstraZeneca, is founder/shareholder of Odyssey Biosciences, has shares in Totus Medicines, and personal consulting fees from Sanofi, Novartis, Inivata, Lilly and AstraZeneca. J.E.R. has received personal honoraria/consulting fees from BMS, Merck, Pfizer, Pharmacyclics, Boheringer Ingelheim, EMD-Serono, GSK, Infinity, Janssen, Mirati, BioClin, Lilly, Tyra Biosciences, Astellas, Seagen, Bayer, AstraZeneca, Roche/Genentech and QED Therapeutics, and conducted trials from Astellas, Seagen, Bayer, AstraZeneca, Roche/Genentech and QED Therapeutics. S.R.S. is an equity holder and member of the scientific advisory board of NeuScience, Inc. and a consultant at Third Bridge Group Limited. D.B.S. has consulted/received honoraria from Rain, Pfizer, Fog Pharma, PaigeAI, BridgeBio, Scorpion Therapeutics, FORE Therapeutics, Function Oncology, Pyramid and Elsie Biotechnologies, Inc. None of these disclosures are directly related to this study. The other authors declare no competing interests.
